EMEnRose Magazine

Arendai, Inc., a pioneer in the delivery of innovative software management solutions for orchestration of logistics center operations, is a Platinum Sponsor of the upcoming Autonomous Mobile Robots & Logistics Week by the A3 Association for Advancing Automation Oct. 10-13 in Boston, Massachusetts. 

Walter Buga, CEO of Arendai, will be speaking in the round table panel discussion "From the Warehouse to the Factory Floor and Beyond: Trends in Mobile Robotics and Automation." Dr. Buga will be sharing his valuable insights on the industry and the future of automation.   

Arendai will be exhibiting its innovative software product Harmony on the conference floor with a product presentation and demos of: 

• A Digital Twin of a sample warehouse  
• AMRs and autonomous forklift orchestration  
• AMRs for products pickup  
• Forklifts for pallets transportation  
• Fleet orchestration backend  

About Harmony 

Arendai's Harmony is an orchestration software solution that delivers optimal management, control, and coordination of humans and AMRs for more successful autonomous logistics center operations. 

Our Harmony product is critical for scalable growth and increased ROI for the logistics centers of the future, as it provides holistic optimization from a fully integrated solution while eliminating paperwork and human errors.  

About Arendai 

By applying simulation, Digital Twin, and AI, Arendai delivers optimal orchestration of heterogeneous AMRs and robotics solutions.  

Arendai has excellent, engaged ecosystem partners with a focus on solving real customer problems and producing an attractive ROI.   

Arendai is a member of the Intel® Network Builders program. 

TwinsSync ™ is an Arendai registered trademark. 

Visit www.arendai.com and follow us on LinkedIn and YouTube.  

Post-Pandemic Job Search - CareerAddict Study
Jobseeker waiting to be seen

A recent study by CareerAddict, a leading, online career resource, has uncovered the latest job search trends in today's post-pandemic era. The 'Shift in Worker Expectations Post-Pandemic' study aims to explain the elements that comprise the driving force behind the Great Resignation, a term coined by organizational psychologist Anthony Klotz to describe the high, ongoing quit rates around the world.

A significant finding of the study was that 71% of jobseekers agreed that COVID-19 changed the type of work they were looking for. Among the main reasons for this collective shift in direction were the increased desire for flexibility and concerns around health, safety, and hygiene.

As Christopher Thoma, Head of Media & Marketing at CareerAddict, stated, "Prior to the pandemic, a healthy work environment wasn't much of a consideration for most workers. Fast forward to 2022, it's become an incredibly important factor..."

The survey also found that 60% of employees left their jobs in search of healthier work environments. Low pay, a lack of advancement opportunities, and feeling disrespected were the top reasons for job dissatisfaction. These factors fueled the Big Quit momentum even at a time of increased uncertainty caused by COVID-19. According to the data, 41% of jobseekers were not hindered by COVID-19 in their efforts to find better opportunities.

While this was anticipated, a surprising conclusion derived from the study was that 61% of jobseekers said the opportunity to work remotely was not a job search factor for them. Unlike previous years, remote work seems to no longer be considered as an important benefit by employees. The only age group that expressed a preference were jobseekers aged between 55 and 64, with 59% stating that remote work had been a search criterion in their job search.

As the job market undergoes notable changes, companies must continuously reassess their approach to hiring. While COVID-19 caused many people to reevaluate their needs and priorities, both on a personal and professional level, good pay, a healthy work environment, and progression opportunities are now the most desirable employment factors for jobseekers.

It appears that companies that fail to reward and value their staff will not only fail to attract new talent but also lose the fight against plummeting retention rates.

To see the full study PDF and all findings, visit https://www.careeraddict.com/.

About CareerAddict

CareerAddict is one of the world's leading career resources, offering expert advice and industry knowledge to its audience of career-enthused individuals. Since launching in 2013, CareerAddict is focused on providing jobseekers, students, workers and employers all over the world with all the necessary tools and resources they need to achieve their professional aspirations.

Contact Information

For additional information or media inquiries, contact Joanna Zambas at [email protected]

L-Nutra, Inc., the world's leading nutrition technology company pioneering the discovery, design, and commercialization of novel nutrition solutions, today announced data in Cell Reports demonstrating the effects of fasting-mimicking diets (FMD) in animal models of Alzheimer's disease and early human safety data. The study reports that FMD cycles reduce cognitive decline and Alzheimer's disease pathology in mouse models. The early clinical data also suggest that FMD cycles are safe and feasible in a small group of Alzheimer's patients. 

Alzheimer's disease is a neurodegenerative disease characterized by progressive memory loss and a decline in quality of life and lifespan. An estimated 6.5 million Americans aged 65 and older live with Alzheimer's dementia, and approximately 200,000 under age 65 have early-onset Alzheimer's. The number of people affected globally by dementia is expected to increase to 152.8 million cases in 2050, primarily due to population aging. FDA-approved drugs for Alzheimer's only temporarily improve or slow the deterioration of Alzheimer's symptoms but do not generally affect disease progression. 

"L-Nutra is the world's pioneering Nutri-Technology company bringing the revolutionary Fasting-Mimicking Technology (FMT) to transform the paradigm of care in four major chronic illnesses: cancer, diabetes, autoimmune diseases, and Alzheimer's. With this published result, our FMT platform takes another bold step towards turning 'food into medicine.' Leveraging the rigor of the biotech industry, we are the leading nutrition company to have a nutrition solution with the potential to impact human longevity and the course of many chronic health conditions," said Joseph Antoun, M.D., Ph.D., CEO and Chairman of L-Nutra, Inc. 

In this newly published paper, the lead author Professor Valter Longo at USC and investigators from other centers* show that cycles of FMT attenuate cognitive decline, reduce Alzheimer's pathology and neuroinflammation, and promote neurogenesis and improve cognition in Alzheimer's mouse models. In a pilot human trial included in the publication, the authors also show that the intervention is safe and feasible in a small group of Alzheimer's patients.

"The patented FMT in previously published studies demonstrated a clear mechanism of action, supported by successful early human trials that showed safety and efficacy in diabetes and various forms of cancer. This exciting result in a neurodegenerative condition extends the finding that the FMT platform as a unique solution has an upstream and overarching systemic impact on the body," said Dr. William Hsu, MD, Chief Medical Officer of L-Nutra, Inc. 

L-Nutra plans to evaluate further its FMT platform's impact on driving various chronic conditions into remission or regression. For more information on L-Nutra and its revolutionary approach to targeting a broad spectrum of diseases, visit www.l-nutra.com or contact Dr. William Hsu, Chief Medical Officer, at [email protected].

*Collaborating centers include USC, IFOM, University of Genoa, UCLA, University of Illinois at Chicago, and University of Perugia.

About L-Nutra Inc.

L-Nutra is leading the discovery, design, and commercialization of novel nutri-programs with the mission of adding more life to human life. Current commercial products focus on wellness and healthy aging, including ProLon®, the first and only clinically tested 5-day fasting nutrition program designed to allow your body to enter a fasting state while still allowing you to consume nutrient-dense foods. L-Nutra created the 1-day fasting nutrition kit ProLon Reset™ and ProLon Intermittent Fasting Bar®, the first nutrition bar specifically designed and clinically tested to support intermittent fasting. Nutrition for Longevity® is L-Nutra's science-backed, chef-curated meal program, featuring farm-to-table meals formulated to address the nutritional deficiencies in today's commercially grown produce. For more info, visit https://l-nutra.com/.